Epeius Pharma
Delivery of Therapeutic Proteins into the Central Nervous System
Company Overview
Snapshot
Founded in February 2019 by Prof. Oded Rechavi and Shahar Bracha, Epeius Pharma operates with 1–10 employees. The company has secured $3.5M in total capital across one funding round from two investors. In January 2020, FutuRx, Ramot at Tel-Aviv University, and Glasgow University jointly launched Epeius Pharma to advance treatments for complex neurological diseases.
Business overview
Epeius Pharma is a cell and gene therapy company focused on developing biological vehicles for delivering therapeutic proteins into the central nervous system. Its platform aims to provide an effective and scalable strategy for disease medication in neurodevelopmental and neurological pathologies that could benefit from direct neuron protein replacement treatments. The company's initial target indication is Rett syndrome, operating within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals and Drug Delivery.
Strategic signal
In January 2020, Epeius Pharma was launched as a collaborative effort between FutuRx, Ramot at Tel-Aviv University, and Glasgow University, signaling a strategic validation of its approach to developing treatments for complex neurological diseases. This partnership highlights the company's strong academic foundation and its potential to translate cutting-edge research into therapeutic solutions, attracting investor interest in the neurodevelopmental and neurological pathology space.
Company Intelligence Q&A
- What is Epeius Pharma's primary focus?
- Epeius Pharma specializes in cell and gene therapy, developing biological vehicles for the delivery of therapeutic proteins into the central nervous system.
- When was Epeius Pharma founded?
- Epeius Pharma was founded in February 2019.
- Who are the founders of Epeius Pharma?
- Epeius Pharma was founded by Prof. Oded Rechavi and Shahar Bracha.
- What is Epeius Pharma's initial target indication?
- Epeius Pharma's first target indication for its therapeutic protein replacement treatments is Rett syndrome.
- Which entities launched Epeius Pharma?
- In January 2020, FutuRx, together with Ramot at Tel-Aviv University and Glasgow University, launched Epeius Pharma to develop treatments for complex neurological diseases.